Detail
| LncRNA Name | ANRIL |
| Synonyms | CDKN2B-AS1, ANRIL, CDKN2B-AS, CDKN2BAS, NCRNA00089, PCAT12, p15AS |
| Region | GRCh38_9:21994778-22121097 Sequence |
| Ensembl | ENSG00000240498 |
| RefSeq | NR_003529 |
| Circulating | ✘ |
| Drug-resisitant | ✘ |
| Prognostic | ✔ |
| MiRNA | ✘ |
| Variant | ✘ |
| TF | ✔ |
| Methylation | ✘ |
| Cancer Name | nasopharyngeal cancer |
| ICD-0-3 | C11 |
| Methods | RT-qPCR, Western blot, Luciferase reporter assay, in vitro knockdown, RIP |
| Sample | NPC cell lines (C666-1, SUNE-1, CNE1, CNE2 and HNE-1) |
| Expression Pattern | up-regulated |
| Function Description | Mechanistically, SOX2 binds with ANRIL and increases its RNA level, which upregulates B-catenin signalling, resulting in enhanced nasopharyngealcarcinoma tumourigenesis. Expression levels of ANRIL are positively correlated with SOX2 and B-catenin in clinical nasopharyngeal carcinoma samples.The transcription factor SOX2 is widely recognized for its pivotal roles during mammalian embryogenesis. |
| Pubmed ID | 29463902 |
| Year | 2018 |
| Title | Upregulation of SOX2-activated lncRNA ANRIL promotes nasopharyngeal carcinoma cell growth. |
| External Links |
| Links for ANRIL | GenBank HGNC lncrnadb Noncode |
| Links for nasopharyngeal cancer | Omim Cosmic |
CopyRight © College of Bioinformatics Science and Technology, Harbin Medical University, China.